Evidence map›Paper›PMID 35443989›Full record

ArticleeNeuro

VGLUT3 Ablation Differentially Modulates Glutamate Receptor Densities in Mouse Brain.

Karim S Ibrahim, Salah El Mestikawy, Khaled S Abd-Elrahman, Stephen S G Ferguson

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in eNeuro. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 64% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. VGLUT3 Deletion Rescues Motor Deficits and Neuronal Loss in the zQ175 Mouse Model of Huntington's Disease.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 4 countries.

Karim S IbrahimBrain and Mind Research Institute, University of Ottawa, Ottawa, Ontario K1H 8M5, Canada.
Salah El MestikawyNeuroscience Paris Seine-Institut de Biologie Paris Seine (NPS-IBPS) INSERM, CNRS, Sorbonne Université, 75006 Paris, France.ORCID https://orcid.org/0000-0002-6253-0002
Khaled S Abd-ElrahmanBrain and Mind Research Institute, University of Ottawa, Ottawa, Ontario K1H 8M5, Canada sferguso@uottawa.ca kshabdel@ucalgary.ca.ORCID https://orcid.org/0000-0001-9724-1975
Stephen S G FergusonBrain and Mind Research Institute, University of Ottawa, Ottawa, Ontario K1H 8M5, Canada sferguso@uottawa.ca kshabdel@ucalgary.ca.
University of Ottawa · CACentre National de la Recherche Scientifique · FR

Funding

CIHR PJT-148656CIHR PJT-165967CIHR PJT-178060
6 · The paper itself

Abstract

Type 3 vesicular glutamate transporter (VGLUT3) represents a unique modulator of glutamate release from both nonglutamatergic and glutamatergic varicosities within the brain. Despite its limited abundance, VGLUT3 is vital for the regulation of glutamate signaling and, therefore, modulates the activity of various brain microcircuits. However, little is known about how glutamate receptors are regulated by VGLUT3 across different brain regions. Here, we used VGLUT3 constitutive knock-out (VGLUT3

Indexed as

Amino Acid Transport Systems, AcidicVesicular Glutamate Transport ProteinsAnimalsBrainCorpus StriatumGlutamic AcidMiceAmino Acid Transport Systems, AcidicGlutamic AcidSlc17a8 protein, mouseVesicular Glutamate Transport ProteinsbrainglutamateGPCRsynaptic plasticitytransporter

Identifiers

PMID35443989
PMCPMC9087739
OpenAlexW4224303515

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.